Your consent is voluntary; however, if you do not consent to cookies being installed on your browser, Allergan may not be able to provide you full access to or all the functionality of our websites. Read more. If you have any questions about artificial tears, dry eye treatment or any other eye related questions, feel free to contact Summit Eye Center at or email This email address is being protected from spambots. You need JavaScript enabled to view it. Kevin R. Skelsey, M.
Obtaining his ophthalmology residency training at Parkland Memorial Hospital, Dr. Skelsey now provides a wide variety of ophthalmology services. Skelsey is a Fellow of the American College of Surgeons. He is a member of several medical organizations and has served as a past president of the Missouri Society of Eye Physicians and Surgeons.
Kelsey J. Kleinsasser, O. Completing a residency in cornea and refractive surgery, Dr. Kleinsasser also provides a wide variety of eye care services.
If you think you have Dry Eye symptoms, make an appointment with your eye doctor. He or she can determine the treatment that is appropriate for you. Please speak with your eye doctor regarding the appropriate treatment for you. Chronic Dry Eye is a disease that requires ongoing therapy, as over time it can have potential consequences for your eyes. Refresh Optive Advanced Preservative-Free is available in count, single-use vials, as well as a preserved multi-dose formula.
Both may be used in combination with dry-eye prescription therapies and do not require shaking prior to use. For more information, visit refreshbrand. FCI Ophthalmics has introduced a line of devices and instruments designed to provide retina surgeons with high-performance products for vitreoretinal procedures. A range of instruments and hand-pieces made from lightweight and durable titanium in several gauges are also available, including Retilock, a one-step self-retaining trocar system for easy access to the posterior segment.
For information, call 1 , fax , or e-mail info fci-ophthalmics. Alcon announced the launch of Ilevro Suspension, a new once-daily treatment option for pain and inflammation associated with cataract surgery. In two double-masked, randomized clinical trials, Ilevro Suspension demonstrated superior clinical efficacy compared to its vehicle. In the studies, patients treated with Ilevro Suspension were less likely to have ocular pain and measurable signs of inflammation cells and flare at the end of treatment than those treated with its vehicle.
Patients administered Ilevro Suspension experienced superior outcomes when compared to those on vehicle in the following areas:. The most frequently reported ocular adverse reactions following cataract surgery were capsular opacity, decreased visual acuity, foreign body sensation, increased intraocular pressure and sticky sensation.
These reactions occurred in approximately 5 to 10 percent of patients. For more information, visit alcon.
0コメント